pharmaphorum

JUNE 4, 2021

The inaugural Prostate Cancer Drug Development Summit is the only industry-led meeting uniting large pharma, biotech and pioneering academics with the ambitious objective of accelerating the clinical development of safe and effective therapies to treat prostate cancer. Bringing theranostics to prostate cancer.

Drug Development 98

Drug Development 98

Pharma Leaders

APRIL 25, 2023

The FDA has granted Fast Track designation to Lantheus and Point Biopharma’s 177Lu-PNT2002 for the treatment of metastatic castration-resistant prostate cancer. Related Topics 117Lu-PNT2002 is currently under a phase 3 clinical trial setting, with enrollment complete and top-line data expected in the second half of this year.

52

52

Pharma Leaders

APRIL 12, 2023

Sumitomo Pharma Oncology has received FDA’s Orphan Drug designation for its TP-1287 candidate to treat Ewing sarcoma, a rare cancer that typically occurs in children or teenagers. TP-1287 is an oral CDK9 protein inhibitor, which has been shown to inhibit tumor growth in preclinical models of blood cancers and several tumor types.

52

52

pharmaphorum

JANUARY 18, 2022

Targeted agents and immunotherapies are two of the most promising areas for significant advancements in cancer treatment. Envision Pharma’s scientific solutions division lead Rebecca Goldstein, discusses this topic and other developments that cancer patients and their loved ones should be paying attention to.

98

98

RX Note

JULY 15, 2023

Standard treatment modalities for the management of these patients are centred around the use of topical antiinflammatory preparations and moisturization of the skin, but patients with severe disease may require phototherapy or systemic treatment. pimecrolimus and tacrolimus) is effective in controlling pruritus.

52

52

pharmaphorum

AUGUST 25, 2022

Today on the pharmaphorum podcast, Editor in Chief Jonah Comstock welcomes Hedi Ben Brahim and Eric Quéméneur, CEO and chief science officer respectively of Transgene, to discuss cancer vaccines in general and Transgene’s recent work in the space in particular. . Podbean. .

Vaccines 52

Vaccines Immunity Immunization 52

Digital Pharmacist

NOVEMBER 1, 2022

November is Lung Cancer Awareness Month. Lung Cancer is the leading cause of cancer deaths in the US, and about every 2 and a half minutes, someone learns they have this disease. Many organizations are working together to defeat lung cancer and during the month of November, it’s critical to raise awareness. Background.

Pharmacy Management 98

Pharmacy Management 98

pharmaphorum

DECEMBER 2, 2022

A new global prostate cancer awareness campaign developed by biopharmaceutical companies AstraZeneca (AZ) and Merck & Co. Prostate cancer is the second most common cancer in men globally, and it affects millions of people around the world indirectly. Never miss a goal. Never miss a chance at early diagnosis.

71

71

RX Note

JULY 16, 2023

Although topical corticosteroids are frequently used in clinical practice , there is little evidence that they are beneficial in reducing the symptoms and healing time of sunburn. Management Sunburns are a self-limiting condition that typically resolve within a few days to a week without treatment.

Mayo Clinic 52

Mayo Clinic 52

Pharmaceutical Technology

FEBRUARY 16, 2023

The University of Texas MD Anderson Cancer Center has entered a strategic collaboration with biotech company Xilis for advancing new technology and expediting new cancer therapy development. Topic sponsors are not involved in the creation of editorial content.

Drug Development 96

Drug Development Communication 96

Pharmaceutical Technology

APRIL 21, 2023

positive pancreatic cancer (PC). positive solid tumours by focusing primarily on gastric cancer/gastroesophageal junction cancer (GC/GEJ) and PC. CARsgen chief medical officer Dr Raffaele Baffa said: “Pancreatic cancer remains a deadly disease with a dismal prognosis and lack of effective therapies. It targets CLDN18.2

59

59

pharmaphorum

JULY 19, 2022

The FDA’s decision to clear the new indication for the topical JAK1/JAK2 inhibitor came after a priority review that was delayed by a request for additional data by the regulator, holding back a decision by three months. million people in the US.

Labelling 98

Labelling 98

Pharmaceutical Technology

JUNE 10, 2023

TAS-117 overview TAS-117 is under development for the treatment of solid tumors including FGFR1 squamous cell lung cancer, ovarian clear cell carcinoma, endometrial cancer, breast cancer, colon cancer, ovarian cancer, cervical cancer, head and neck cancer, thyroid cancer, chondrosarcoma and g-PTEN aberrations cancer.

Drug Development 40

Drug Development 40

Pharmaceutical Technology

JUNE 10, 2023

TAS-117 overview TAS-117 is under development for the treatment of solid tumors including FGFR1 squamous cell lung cancer, ovarian clear cell carcinoma, endometrial cancer, breast cancer, colon cancer, ovarian cancer, cervical cancer, head and neck cancer, thyroid cancer, chondrosarcoma and g-PTEN aberrations cancer.

Drug Development 40

Drug Development 40

Pharmaceutical Technology

DECEMBER 8, 2022

Directed against a cell membrane protein called CD19, Yescarta uses the immune system of the patient to destroy cancer. On infusing back to the patient, this approach aids the T cells in detecting and killing cancer cells. . Topic sponsors are not involved in the creation of editorial content. Free Whitepaper.

Communication 122

Communication Immunity Immunization Hospitals 122

Pharma Marketing Network

DECEMBER 6, 2021

NEW YORK, December 6 th , 2021 (PRNEWSWIRE) – Tap Native, the leading health-focused content discovery platform, today unveiled a list of the top 20 most popular health topics viewed by consumer audiences in 2021. million unique URLs across the top 100 largest health websites in its network to determine which topics were viewed most.

Diabetes 52

Diabetes Immunity Immunization Vaccines 52

Pharmaceutical Technology

APRIL 14, 2023

The company and the researchers, with Professor Krishanu Saha as principal investigator (PI) and Dr Christian Capitini as co-PI, will develop a GD2 CAR T-cell therapeutic candidate to treat neuroblastoma, a cancer type that generally affects young children. Topic sponsors are not involved in the creation of editorial content.

105

105

Pharmaceutical Technology

JANUARY 17, 2023

The Spanish Association Against Cancer (AECC) provided funding for the new STAb therapy development. The future in cancer and leukaemia research lies in the creation of personalised therapies that provide options for all those who today find no alternative to conventional therapies. STAb-T therapy is on this path.”. Free Whitepaper.

Hospitals 110

Hospitals Chemotherapy Communication Immunity 110

pharmaphorum

OCTOBER 6, 2022

The new version – dubbed Florence 2.0 – covers a broader range of topics. The topics chosen for Florence are some of those that have the greatest burden on health around the world, and according to her developers she could help support healthcare workers in areas where there are shortages in healthcare staff.

Diabetes 145

Diabetes Vaccines 145

Putting Patients First Blog

FEBRUARY 29, 2024

In its 32-year history, the CDMRP has funded research into a plethora health care issues that impact the chronic illness community including breast cancer, chronic pain management, epilepsy, melanoma, multiple sclerosis, etc. By the 1990s, more advocacy groups such as the American Cancer Society and Susan G.

52

52

Pharmaceutical Technology

MAY 1, 2023

Under the deal terms, Shunxi will have licence to develop, manufacture, and commercialise CTH-004 to treat several solid tumours including ovarian cancer in Greater China, including Hong Kong, Taiwan, Mainland China, and Macao. In animal models of ovarian cancer, it demonstrated promising results.

52

52

Pharmaceutical Technology

APRIL 20, 2023

Circio aims to develop new circRNA medicines initially for cancer, then plans to expand rapidly into vaccines and gene therapy. CircAde is said to be the most advanced therapeutic concept, and leverages the company’s experience in oncolytic viruses to use engineered adenoviruses to deliver circRNA to cancer cells.

Vaccines 96

Vaccines 96

Dr. Neal Smoller

DECEMBER 2, 2022

That includes cancer, heart disease, stroke, and all the number one killer diseases in the United States. Topics Discussed The Reality of Health Statistics in the US Heart Problems, Heart Attacks, and Heart Health The Truth of an Unhealthy Wellness Practice.

52

52

Pharmaceutical Technology

SEPTEMBER 29, 2022

Scribe Therapeutics and Sanofi have signed a strategic partnership to expedite the development of breakthrough clustered regularly interspaced short palindromic repeats (CRISPR)-based cell therapies for cancer. Topic sponsors are not involved in the creation of editorial content.

52

52

pharmaphorum

AUGUST 14, 2020

Screening women for breast cancer in their 40s rather than their 50s could save lives, say the authors of a new Lancet Oncology study, although that finding has been challenged by other experts. Overall, the number of deaths per 10,000 women was 16 in the screening group and 21 for the controls.

106

106

Pharmaceutical Technology

APRIL 21, 2023

Samyang has entered into a strategic partnership agreement with LG Chem to develop new cancer therapeutics using Samyang’s technology, NanoReady. LG Chem will use the technology for the development of innovative mRNA-based cancer therapeutics with maximised therapeutic efficacy.

Drug Development 52

Drug Development 52

European Pharmaceutical Review

AUGUST 22, 2023

Winners of a series of competitions centering on the aforementioned topics will obtain funding for UK medicines manufacturing. The investment aims to improve vaccines and shorten the time it takes to produce medicines. Seventeen new projects from the Innovate UK Transforming Medicine Manufacturing programme will benefit.

Vaccines 93

Vaccines Packaging 93

The Honest Apothecary

MAY 4, 2023

I might throw in a something off-topic from time to time which I found while wandering throughout the endless hallways and corridors of the internet. Experts expect it to become the leading cause of cancer death in individuals aged 20-49 in the U.S. All article shared will be free to read and not locked behind an annoying paywall.

84

84

Pharmaceutical Technology

FEBRUARY 19, 2023

Danburstotug is under clinical development by Sorrento Therapeutics and currently in Phase III for Cervical Cancer. According to GlobalData, Phase III drugs for Cervical Cancer have a 68% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration.

Drug Development 40

Drug Development 40

European Pharmaceutical Review

OCTOBER 13, 2022

Shriya Srinivasan was lead author on the study and research affiliate at MIT’s Koch Institute for Integrative Cancer Research and a junior fellow at the Society of Fellows at Harvard University. The spinning action helps to erode the compartment that carries the drug, so the drug can be gradually released into the digestive tract.

137

137

Pharmaceutical Technology

JUNE 7, 2023

Acepodia will use the proceeds from the Series D round to advance its cell therapies pipeline, including ACE1831 and ACE2016, to treat solid tumours and haematologic cancers. ACE1931 is an off-the-shelf therapy targeting CD20-expressing haematological cancers. Topic sponsors are not involved in the creation of editorial content.

59

59

pharmaphorum

DECEMBER 23, 2022

Johnston also shares how she revelled in the wide range of discussions held at Anthropy, while the notion of change was a hot topic. As a hospice movement, the proportion of cancer patients is dropping, but comorbidities and dementia cases are increasing.

52

52

Pharmaceutical Technology

OCTOBER 14, 2022

The two companies will aim to improve the manufacturing and analytic procedures used to develop personalised cell and gene therapies to treat cancer patients. We look forward to supporting aCGT and their initiatives, including the next-generation cell therapies for the cancer-focused HEALED Consortium.”.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies 52

pharmaphorum

JANUARY 13, 2022

AstraZeneca has expanded its efforts to develop new therapies targeting transcription factors – proteins that regulate processes in the cell that have become a hot topic for drug discovery in cancer and other diseases. The post AZ, Scorpion strike deal on elusive transcription factor targets in cancer appeared first on.

58

58

PharmaShots

MARCH 30, 2023

Equity investment into Galimedix supports Galimedix's pipeline development TOI gets an exclusive right to develop & commercialize Galimedix’s GAL-101 for topical & oral treatment of dry AMD, glaucoma & other ophthalmic indications in the EU, the Americas, the Middle East & Africa.

40

40

Pharmaceutical Technology

NOVEMBER 29, 2022

Neogene focuses on discovering, developing and producing next-generation T-cell receptor therapies (TCR-Ts) that provide a new cell therapy approach for fighting cancer. TCR-Ts can detect intracellular targets such as cancer-specific mutations to unlock targets which were not accessible earlier using cell therapies. Free Whitepaper.

Communication 111

Communication 111

pharmaphorum

DECEMBER 9, 2020

COVID-19’s knock-on effect on cancer patients is of concern by HCPs, with delayed or decreased diagnosis seen as a key worry. A key concern that has emerged from the crisis is how COVID-19 will affect other areas of healthcare, particularly cancer diagnosis and treatment. HCPs concern for decreased cancer diagnosis.

Hospitals 124

Hospitals Clinic Management Communication Pharmaceutical Companies 124